The data suggested development of an in vivo SASP, the index of which can be technically measured by quantifying the concomitantly expressed SASP factors including but not limited to AREG and IL‐8 in the peripheral blood of post‐treatment cancer patients. This evidence concerns the gene CXCL8 and cancer.